JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data

Janus kinase (JAK) Inhibitors are the latest drug class of disease-modifying medication to emerge for the treatment of rheumatoid arthritis (RA). They are a small molecule-targeted treatment and are the first oral option to compare favourably to existing biologic disease-modifying anti-rheumatic dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrington, Robert, Al Nokhatha, Shamma Ahmad, Conway, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500842/
https://www.ncbi.nlm.nih.gov/pubmed/32982367
http://dx.doi.org/10.2147/JIR.S219586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500842/
https://www.ncbi.nlm.nih.gov/pubmed/32982367
http://dx.doi.org/10.2147/JIR.S219586

Ejemplares similares